HLA-DRB1 and myeloid sarcoma: Through comparing hub common susceptibility genes and target genes of available drugs, we found that IL2RA and HLA-DRB1 that were identified as hub common susceptibility genes were the targets of daclizumab and glatiramer acetate, respectively, which were approved drugs of MS.